EFFISAYIL OBSERVE: A real-world descriptive study of patients with generalized pustular psoriasis (GPP) in the USA
Main Article Content
Keywords
Generalized Pustular Psoriasis, Non-interventional, Observational, Real-world study
Abstract
• GPP is a chronic, neutrophilic inflammatory disease, driven by dysregulation of theinterleukin-36 pathway, and associated with systemic symptoms and high disease burden.
• The estimated prevalence of GPP in the USA is 0.9 per 10,000 individuals.
• Given the rarity of GPP, real-world data describing treatment patterns and HCRU associated with the disease are limited.
• To address this knowledge gap, the EFFISAYIL OBSERVE study collected real-world data from the medical records of a representative cohort of patients with GPP in the USA.
References
2. Armstrong AW, et al. J Am Acad Dermatol 2024;90:727–30.
3. Puig L, et al. J Eur Acad Dermatol Venereol 2023;37(4):737–52.
4. Noe MH, et al. J Psoriasis Psoriatic Arthritis 2025; 10(2):51–7.
5. Boehringer Ingelheim. Press release. https://www.boehringer-ingelheim.com/humanhealth/skin-and-inflammatory-diseases/gpp/us-fda-approves-first-treatment-generalizedpustular-psoriasis-flares-adults. Accessed September 9, 2025.
Article Sidebar
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
Creative Commons Attribution (CC BY): lets others distribute and copy the article, to create extracts, abstracts, and other revised versions, adaptations or derivative works of or from an article (such as a translation), to include in a collective work (such as an anthology), to text or data mine the article, even for commercial purposes, as long as they credit the author(s), do not represent the author as endorsing their adaptation of the article, and do not modify the article in such a way as to damage the author's honor or reputation.
Authors retain copyright in their work and license the publisher to publish the content. The publisher is the National Society for Cutaneous Medicine, with production and publishing support provided by OJS, Open Journal Systems,see https://pkp.sfu.
Prior to January 2022, authors transferred copyright to the National Society for Cutaneous Medicine. However, all articles are freely available to anyone in the world. There are no subscription fees, page charges, or article processing charges.